Biocytogen’s TCR-mimic (TCRm) antibody platform can be deployed to generate antibodies in vivo to target pHLA complexes for mutated proteins, viral oncoproteins, and cancer-testis antigen (CTA)
Germline gene usage and avidity assessments demonstrate the diversity of TCRm antibodies that can be
generated using the platform
When assembled via a T Cell engager strategy, TCRm sequences discovered using our platform demonstrate the ability to kill tumor cells in an antigen-specific manner
